The research team, working with mouse models spanning young adults to very old animals, first documented that aging is accompanied by an increase in CaMKII abundance. In the tibialis anterior muscles of 33-month-old mice, total CaMKIIβ and CaMKIIδ/γ protein levels were significantly elevated compared with 3.7-month-old controls, and so were the T287 autophosphorylation signals that serve as a biochemical marker of kinase activation. These aged animals also showed the expected reductions in normalized muscle mass across the tibialis anterior, gastrocnemius, and quadriceps. The authors were careful to note, however, that steady-state autophosphorylation may not fully capture chronic CaMKII signaling, because the kinase is also regulated by calcium/calmodulin binding, oxidation, nitrosylation, and O-GlcNAcylation. That ambiguity set the stage for a more direct experimental question: is sustained CaMKII activation sufficient to drive muscle dysfunction on its own?

To answer it, the researchers used adeno-associated virus serotype 9 to deliver a constitutively active form of CaMKIIγ, carrying a phosphomimetic T287D mutation, into the tibialis anterior muscles of young mice under a muscle-specific promoter. Each animal received the active kinase in one leg and a green fluorescent protein control in the other, allowing paired comparisons within the same mouse. The construct expressed at levels comparable to endogenous CaMKII, and although the transgene triggered a feedback reduction in endogenous CaMKII abundance and autophosphorylation, kinase assays and a fluorescent CaMKII activity reporter called CaMKAR confirmed that net enzymatic activity was clearly elevated in the injected muscles.

The functional consequences were striking. Six weeks after gene transfer, muscles expressing the constitutively active kinase produced significantly less force than their paired controls across the entire 1–150 Hz stimulation range, and the deficit persisted even after normalizing force to muscle mass. Mediation analysis showed that the early loss of contractile strength was almost entirely a direct effect of CaMKII signaling rather than a byproduct of the modest 7 percent reduction in muscle mass that had developed by seven weeks. In other words, the muscle was genuinely weaker, not merely smaller. Only with much longer activation did atrophy become a dominant factor: nine months after injection, muscle mass had fallen by 24.2 percent, and mediation analysis then attributed the bulk of the force decline to the loss of tissue itself.

Under the microscope, the CaMKII-activated muscles revealed a distinctive pattern of structural remodeling. There was no inflammation or necrosis, but affected fibers showed abnormal basophilic staining, intensified subsarcolemmal and intrafiber signals on modified Gomori’s trichrome staining, and aggregated mitochondrial enzymatic activity on cytochrome c oxidase and succinate dehydrogenase stains. Electron microscopy made the picture explicit: mitochondria clumped beneath the sarcolemma and between myofibrils, and a quantitative Z-line mitochondrial occupancy score dropped significantly at both seven weeks and five months. Importantly, this was a problem of geography rather than quantity. Respiratory chain subunit abundance and the mitochondrial-to-nuclear DNA ratio were unchanged, indicating that sustained CaMKII signaling scatters mitochondria away from their normal posts near the calcium release units and Z-lines without depleting them.

That mislocalization matters because intermyofibrillar mitochondria in adult muscle are normally positioned to deliver ATP locally for cross-bridge cycling and calcium reuptake, and to take up calcium during activity in a process known as excitation–metabolism coupling. Aging is known to disrupt precisely this arrangement, reducing the apposition between calcium release units and mitochondria in both aged mouse and human muscle. The authors propose that CaMKII-driven disruption of cytoskeletal anchoring, possibly through phosphorylation of desmin and related intermediate filament proteins, or altered mitochondrial dynamics via the fission regulator Drp1, could explain how a calcium-activated kinase ends up scrambling the muscle’s power grid.

The transcriptional evidence was equally compelling. RNA sequencing of young muscles expressing active CaMKII for seven weeks revealed 2,771 differentially expressed genes, and when these changes were correlated with the gene-expression signature of normal aging, the concordance was moderate but highly significant. Of the genes altered with age, 73.5 percent were shifted in the same direction by sustained CaMKII activation. Gene set enrichment analysis against the Reactome database showed that CaMKII activation in young muscle reproduced the aging-associated activation of immune, interferon-gamma, antigen-presentation, DNA-repair, and extracellular-matrix pathways, while suppressing metabolic and structural-remodeling programs. Sustained CaMKII signaling, in effect, pushed the young transcriptome toward an aged profile, though not a complete one, implying that additional pathways cooperate with CaMKII in the full aging program.

Two intervention experiments then tested causality from the opposite direction. When aged mice received AAV9-delivered CN19o, a well-characterized CaMKII inhibitory peptide, their tibialis anterior muscles generated significantly greater absolute force and significantly higher force normalized to muscle mass after five weeks, without any increase in muscle size or fiber diameter. A second cohort using phosphate-buffered saline controls confirmed the effect. Meanwhile, co-expression of a degradation-resistant IκBα super-repressor, which blocks canonical NF-κB signaling, did not prevent the early CaMKII-induced force deficit but partially preserved long-term force at ten months, independently of muscle mass. This places inflammatory NF-κB signaling downstream of CaMKII as one contributor to progressive decline, while pointing to other mechanisms for the acute weakness.

Among those other mechanisms, mediation analysis of matched transcriptomic and force data singled out heme metabolism as the principal transcriptomic correlate of CaMKII-induced weakness. Active CaMKII upregulated genes involved in heme and iron export, including Flvcr1, Abcg2, and the iron exporter Slc40a1, while downregulating genes supporting heme synthesis and iron uptake, such as Fech, Abcb10, Tfrc, and Fth1. Regulatory network inference identified the heme-responsive transcription factor Spic as the top activated factor in CaMKII-expressing young muscle and the top suppressed factor in CN19o-treated aged muscle, a reciprocal pattern consistent with dysregulated heme and iron handling. The authors suggest a model of functional iron deficiency coexisting with labile-iron accumulation, a state that could compromise mitochondrial metabolism and elevate oxidative stress, and one that echoes iron dyshomeostasis previously reported in aging human muscle.

The broader conceptual payoff is an example of what evolutionary biologists call antagonistic pleiotropy: a pathway that is adaptive in youth becomes harmful in old age. Transient CaMKII activation scales with physiological demand and resolves during recovery, supporting performance and exercise adaptation. With aging, declining functional capacity may make everyday activity a relatively greater stress, promoting more persistent CaMKII activation and shifting its effects toward dysfunction. Exercise, on this view, protects muscle not only by inducing beneficial adaptation but also by preserving the functional reserve that keeps chronic homeostatic stress in check. For people who cannot exercise enough, the findings raise the possibility of pharmacological CaMKII inhibition as a complementary strategy, a prospect sharpened by the recent identification of the FDA-approved JAK inhibitor ruxolitinib as a potent CaMKII inhibitor at therapeutic concentrations. The authors caution that their constitutively active kinase model does not perfectly reproduce the magnitude, duration, or isoform composition of endogenous CaMKII dysregulation, and that the relevance to human muscle aging remains to be established. Still, by connecting a self-amplifying calcium signal to mitochondrial mislocalization, an aged transcriptome, heme-iron disruption, and measurable weakness, the study gives sarcopenia research a concrete, druggable molecular thread to pull.

Subject of Research: The role of sustained CaMKII signaling in age-related skeletal muscle contractile dysfunction and sarcopenia

Article Title: Sustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging

Article References: Bene, M. R., Chung, T., Luczak, E. D., Lopez‐Cecetaite, G., Fountain, W. A., Rosales‐Soto, G., Hernández‐Ochoa, E., Antonescu, C., Florea, L., Jeong, S. J., Elassal, E., Le, A., Xue, Q.-L., Hoke, A., Abadir, P. M., & Wang, Q. (2026). Sustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging. Aging Cell, 25(9), Article e70704. https://doi.org/10.1111/acel.70704

Image Credits: AI Generated

DOI: 10.1111/acel.70704

Keywords: CaMKII, sarcopenia, skeletal muscle, aging, mitochondria, calcium signaling, NF-kB, heme metabolism, gene expression, AAV9, CN19o, contractile dysfunction

SUMOylation is the process by which small ubiquitin-like modifier proteins, or SUMOs, are covalently attached to target proteins inside the cell. Far from being a minor decoration, SUMOylation is a master regulator of protein behavior. By conjugating SUMO to transcription factors, chromatin modifiers, signaling proteins and structural components, cells can rapidly alter protein stability, subcellular localization, interaction partners and activity without synthesizing new proteins. The modification is reversible, dynamic and highly responsive to cellular stress, making it an ideal instrument for a tissue that must constantly adapt its gene expression program to changing demands.

Skeletal muscle depends on precisely this kind of coordinated control. Contractile function emerges from the orchestrated expression of myosin heavy chains, actin, troponins, calcium-handling machinery and mitochondrial proteins, all of which must be maintained in strict proportion. When the transcriptional architecture supporting this program falters, the consequences are not simply a loss of muscle mass but a qualitative decline in the muscle’s ability to generate force. This distinction matters clinically, because patients with cancer can lose contractile capacity even when the change in raw muscle volume appears modest.

The new research set out to map how this control system is perturbed when muscle is exposed to a cancer environment. Rather than asking only which genes change, the investigators asked which proteins carry SUMO marks, how the ensemble of SUMOylated proteins shifts, and how those shifts align with changes in transcriptional regulation. The resulting picture is one of global reorientation: the set of SUMOylated targets in cancer-affected muscle differs markedly from that in healthy tissue, implying that SUMO conjugation is redirected toward a new set of substrates as the disease progresses.

At the center of this reprogramming sits L3mbtl2, a member of the mbt-domain family of chromatin-binding proteins. L3mbtl2 functions as a transcriptional repressor, reading methylated histone marks through its mbt domains and helping assemble Polycomb-like repressive complexes that compact chromatin and silence target genes. In muscle, such chromatin-based repression is essential for maintaining fiber-type identity and preventing inappropriate activation of non-muscle programs. The study reports that the transcriptional activity mediated by L3mbtl2 is altered in the setting of cancer-associated contractile dysfunction, indicating that this epigenetic gatekeeper no longer holds its normal regulatory position.

The convergence of SUMOylation and L3mbtl2 is biologically compelling. SUMO modification is known to influence chromatin regulators directly, modulating their ability to bind DNA, recruit co-factors and establish repressive domains. A reoriented SUMOylation landscape could therefore change L3mbtl2’s behavior at chromatin, either by modifying the protein itself or by altering the availability of SUMO-dependent co-regulators in the complex. The net effect described in the paper is a transcriptional state in muscle that diverges from the healthy program, consistent with the observed contractile deficits.

Methodologically, the study exemplifies the current shift in muscle biology from single-readout measurements to systems-level profiling. Global SUMOylation mapping requires enrichment of SUMOylated proteins followed by mass spectrometric identification, an approach that captures hundreds of modified substrates in a single experiment. Aligning that map with transcriptomic data allows researchers to connect post-translational modifications to the gene expression outcomes they help produce. It is this integration that elevates the findings beyond a catalog of altered marks toward a mechanistic model of how cancer distorts muscle gene control.

The clinical implications are potentially significant. If SUMO pathway enzymes or L3mbtl2-dependent chromatin complexes can be shown to drive contractile dysfunction, they would represent a class of therapeutic targets fundamentally different from the nutritional and anti-inflammatory strategies that currently dominate cachexia management. Pharmacological modulation of SUMOylation is already an active area of research in oncology, with inhibitors of SUMO-activating enzyme under investigation for certain cancers. A clearer understanding of how these pathways behave in muscle could open the door to interventions that preserve muscle quality rather than merely slowing its loss, a goal that has remained elusive despite decades of effort.

There are, of course, important caveats. SUMOylation is ubiquitous, and systemic manipulation of the pathway carries risks, given its roles in genome stability, DNA repair and stress responses in virtually every tissue. Any therapeutic strategy would need to achieve tissue selectivity or be directed at a muscle-specific downstream effector such as the L3mbtl2 complex. Further work will also be needed to determine whether the reorientation of the SUMO landscape is a cause of contractile dysfunction or a consequence of it, and whether restoring normal SUMO patterns in preclinical models rescues muscle force output.

Even so, the study adds an important dimension to a growing recognition that epigenetic and post-translational mechanisms lie at the heart of cancer-associated muscle failure. The muscle wasting that shadows malignant disease has long been treated as a metabolic problem, a matter of energy balance and protein turnover. This work reframes it as a problem of information: cancer corrupts the chemical signals that tell muscle genes what to do, and the SUMOylation system, acting through chromatin regulators such as L3mbtl2, appears to be a key carrier of that corrupted message. Decoding that signal with greater precision may ultimately offer patients something that current supportive care cannot: the preservation not just of muscle mass, but of the strength to use it.

Subject of Research: SUMOylation reprogramming and L3mbtl2-mediated transcriptional changes in cancer-associated skeletal muscle contractile dysfunction

Article Title: Reorientation of the SUMOylation landscape and altered L3mbtl2-mediated transcriptional activity in cancer-associated muscle contractile dysfunction

Article References: Reorientation of the SUMOylation landscape and altered L3mbtl2-mediated transcriptional activity in cancer-associated muscle contractile dysfunction. (n.d.). https://doi.org/10.1038/s41420-026-03337-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03337-y

Keywords: SUMOylation, L3mbtl2, cancer cachexia, skeletal muscle, contractile dysfunction, transcriptional regulation, chromatin, post-translational modification, muscle wasting, epigenetics, oncology, Cell Death & Discovery